SCOTTSDALE, Ariz., June 23 /PRNewswire/ -- MedPredict has published a new report designed to provide critical strategic insight for pharma and biotech companies hoping to identify the next blockbuster drug for pain management. The report, entitled "Thought Leader Insight & Analysis: Pain/Analgesics," is based on in-depth interviews conducted with a panel of specialists in anesthesiology, psychiatry, rheumatology, gastroenterology and primary care.
The diagnosis and treatment of nociceptive, neuropathic and somatic pain varies considerably depending on the physician specialty. MedPredict's panelists in each specialty outline their therapeutic goals and unmet needs in treating pain associated with cancer, fibromyalgia, trauma, rheumatoid and osteoarthritis, back injury, neuropathy, depression, migraine and Crohn's disease.
"Pain is subjective," said Dr. Jeffrey Berk, MedPredict's president. "If you think that you hurt, you hurt. This subjectivity makes the diagnosis and treatment of pain exceedingly difficult, and it presents enormous challenges for researchers trying to demonstrate analgesic efficacy versus placebo." One path to success will be to narrowly define the population being studied, as Lilly has done with duloxatine in diabetic neuropathy, according to Dr. Berk.
MedPredict's panelists predict successes and failures in a number of therapeutic targets, including mu receptor agonists/opioids, serotonergic/noradrenergics, sodium and calcium channel blockers, NMDA/glutamate, Alpha-2 agonist, (mGlu2/3), acetylcholine, AMPA, cannabinoid, NF Kappa b, TRPV1/vanilloids, stimulants, NSAIDs, hyaluronic acid, anti-IL-10 and anti-IL-1. They evaluate the development pipeline based on the medical potential, mechanism of action, reimbursement and regulatory environment and relevance of Schedule II status.
Companies/Partnerships discussed in this report include Allergan,
Allergan/Acadia, Alpharma, Alpharma/Institut Biochimique, Amgen,
Copyright©2008 PR Newswire.
All rights reserved